University of Arizona Opens 2-Year Trial of GLP-1 Drugs With Chemotherapy for 3 Metastatic Cancers
Updated
Updated · Medical Daily · Jul 9
University of Arizona Opens 2-Year Trial of GLP-1 Drugs With Chemotherapy for 3 Metastatic Cancers
3 articles · Updated · Medical Daily · Jul 9
Summary
NCT07627191 will test whether GLP-1 receptor agonists can be safely continued with standard first-line chemotherapy in metastatic pancreatic, colorectal and hepatocellular cancer, with completion estimated by June 2028.
More than 1 in 8 U.S. adults have used GLP-1 drugs, leaving oncologists with little evidence on whether patients diagnosed with cancer should continue, pause or stop semaglutide- or tirzepatide-type medicines during treatment.
The study's primary goal is safety—tracking adverse effects, treatment interruptions and other harms—while also gathering early signals on whether GLP-1 use affects chemotherapy efficacy or cancer outcomes.
The trial was not yet recruiting as of July 8, and any results could become the first controlled clinical evidence to guide oncology practice on GLP-1 use during active chemotherapy.
With studies linking GLP-1s to lower cancer risk, could this be the next breakthrough in cancer prevention?
As millions take Ozempic during cancer treatment, are they getting a secret boost or risking dangerous side effects?
Combining GLP-1 Drugs with Chemotherapy: Inside the 2026 University of Arizona Clinical Trial for Advanced GI Cancers
Overview
In July 2026, the University of Arizona Cancer Center launched a groundbreaking clinical trial to test the safety and early effectiveness of combining GLP-1 receptor agonists with standard chemotherapy for patients with advanced pancreatic, colorectal, or liver cancer. This is the first study of its kind, aiming to find out if this new treatment approach can improve patient outcomes. The trial closely monitors for side effects and tracks how well the treatment works, including changes in tumor response, survival, body weight, and quality of life. The results could lead to better therapies for these difficult cancers.